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Under the auspices of the American Hepato-Pancreato-Biliary Association, an expert consensus conference was convened in
January 2010 on the multidisciplinary management of hepatocellular carcinoma. The goals of the conference were to address
knowledge gaps in the optimal preparation of patients with HCC for operative therapy, best methods to control HCC while
awaiting liver transplantation, and developing a multidisciplinary approach to these patients with implementation of novel
systemic therapies.
1.Introduction
HCC has emerged as the 5th most common cancer in the
world and its incidence is increasing in the Western world
[1, 2] In January 2010, the American Hepato-Pancreato-
Biliary Association (AHPBA) convened a consensus confer-
ence on the multidisciplinary management of hepatocellular
cancer (HCC) cosponsored by the Society of Surgical
Oncology, the Society for surgery of the Alimentary Tract
and the The University of Texas MD Anderson Cancer center
[3].Themethodsusedintheconsensusconferencehavebeen
previously described. Brieﬂy consultation within the three
sponsoring organizations identiﬁed experts to participate in
the conference. Each expert was asked to present on a given
area and to outline two or three consensus statements, which
were then reviewed by a panel of content experts and the
audience. After the symposium, the consensus statements
were summarized by the speakers and session cochairs with
input from the corresponding session cochairs. The meeting
was divided into three sessions (1) pretreatment assessment,
(2) surgical treatment, and (3) combined modality therapy
[3]. The following paper provides a concise summary of
the expert consensus statements resulting from the three
sessions.
2.PretreatmentAssessment of
HepatocellularCarcinoma
Currently, there are 18 HCC scoring or staging systems used
intheworld, butbased oncurrentknowledgeand experience
no single staging system is applicable to all patients [4].
Staging systems used should combine extent of liver disease,
general health, and tumor markers as features to provide
guidance in prognosis and treatment. However, the use of
regional staging systems should be discouraged because it
precludescomparison between centers. Most staging systems
studied perform poorly when used in patients with a wide
spectrum of disease, and the discriminatory performance of
diﬀerentstagingsystemsappearstobetreatment, region,and
stage speciﬁc. Given these limitations, the expert consensus
was that the Barcelona Clinic liver cancer (BCLC) is appro-
priate for patients with advanced liver disease who are not
candidates for resection and/or transplantation. BCLC also
provides a reasonable guide for patients in stages B and C
with the caveat that resection may be considered for some
of these patients. The AJCC/UICC classiﬁcation is valid in
the West and East for patients undergoing liver resection,
and should be coupled with the ﬁbrosis score. Pathological
outcome should be reported using the AJCC/UICC system2 International Journal of Hepatology
following resection or liver transplantation. Finally accurate
staging varies based on the modalities used, and optimal
staging guidelines that may include biomarkers should be
established to allow for more precise comparisons between
diﬀerent treatment regimens [4].
2.1.PretreatmentImaging. Imagingisanintegralcomponent
of pretreatment assessment of HCC and severity of liver
disease. Recommendations regarding imaging were that
both Dual CT and MRI should be used for pretreatment
staging in HCC; however, MRI has the best performance
characteristics for the detection of HCC. The use of Dual
CT is also limited by repeated radiation exposure due to
the frequency and length of follow-up imaging required
in the management of patients with HCC and cirrhosis.
Ultrasoundorcontrast-enhanced ultrasound couldbeuseful
for HCC screening; however, the data was insuﬃcient to
make a recommendation. Both MRI and CT have limited
sensitivity and speciﬁcity for detection of lesions <1cm;
however,thenewliverMRliver-speciﬁc agentsare promising
for HCC detection and characterization of small lesions.
Image subtraction and diﬀusion weighted imaging should
be used as markers of treatment eﬃcacy rather than lesion
size. Background liver ﬁbrosis and cirrhosis may be also
assessedbyfunctionalMRIwhichutilizeshepatocyte-speciﬁc
contrast medium [4–6].
2.2. Role of Portal Vein Embolization. Portal vein emboliza-
tion (PVE) has emerged as an important technique of
increasing FLR (futureliver remnant) in patients undergoing
major hepatic resections [7–10]. The consensus regarding
PVE was that patients with potentially resectable disease
should have volumetric analysis of the total liver volume
(TLV) and the anticipated FLR. If major hepatic resection
is indicated, portal vein embolization may be appropriate
when FLR < 20% of TLV in normal liver, <30% of TLV
in chemotherapy associated injured liver, and <40% of TLV
in patients with cirrhosis. Imaging is indicated 3-4 weeks
after PVE and resection is safe when FLR volume reaches
the target. Combination transarterial chemoembolization
(TACE) with lipiodol and an anticancer agent followed by
PVE should be considered for patients with chronic liver
disease beingconsideredformajorresection duetoincreased
hypertrophy and higher tumor responses compared to PVE
alone [4, 11].
2.3. Deﬁning Criteria for Resectability. The deﬁnition for
resectability in HCC broadly includes two main considera-
tions: liver function and tumor characteristics. The MELD
score is useful in determining patients who can safely
undergo major hepatic resection [12]. Minor resection in
Child-PughclassApatientswithportalhypertension, ascites,
bilirubin > 2mg/dL is contraindicated. Resection should
be considered in patients without portal hypertension and
bilirubin < 1mg/dL. Utilizing strict tumor size to determine
resectabilitywasfoundtobeunwarranted.Multifocaltumors
should be considered for resection, whereas multinodular
tumors meeting the Milan criteria should be considered for
transplantation given the high recurrence rates [4].
3.Surgical Treatmentof HCC
Surgical management of HCC involves both nonresectional
ablative techniques and surgical resection. Nonresectional
ablative therapies have emerged as eﬀective treatment
options for patients with HCC with radiofrequency ablation
(RFA) being the most commonly used technique. Percu-
taneous RFA has been found to induce signiﬁcant tumor
necrosis in small tumors away from vascular structures.
Additionally, long-term survival rates after RFA are compa-
rable to resection or liver transplant, (OLT) in patients with
small HCC <2cm[13, 14] .H o w e v e rt h i sa s s e r t i o ni ss t i l lt o
be determined in large randomized trials. Therefore, RFA is
not recommended in resectable patients with tumors >4cm
or in HCC close to major vascular structure, but may be
considered for small tumors away from vascular structures.
Newer ablative therapies such as microwave ablation may be
more eﬀective in treating larger tumors and tumors close
to vessels. However, current data regarding this microwave
ablation and other ablative techniques such as high-intensity
focused ultrasound and electropolation is immature and
therefore deﬁnitive conclusions are not possible [15].
Hepatic resection is the primary treatment for HCC in
selected patients with reported 5yr overall survivals of 25%–
50% [16]. Selection for resection is based on the extent
of the tumor and the severity of liver disease. Multiple
tumors and/or portal hypertension in patients with Child-
Pugh class A liver dysfunction can undergo resection with
acceptable outcomes [17]. Resection with wide margins (1-
2cm) is the treatment of choice for HCC in patients without
cirrhosis orforselectedpatientswithcirrhosis withoutportal
hypertension [16, 18]. Minimizing blood loss and perform-
ing limited resections is associated with better perioperative
outcome, with most centers reporting mortality rates <5%
[19]. The eﬃcacy of resection in patients with large tumors
and major vascular invasion is unclear, and decisions for
surgical therapy in this group of patients must be made on
an individual basis [15, 20]. Laparoscopic liver resection has
been found to be feasible without compromising oncological
outcome in limited clinical reports [21, 22].
Liver transplantation is the optimal treatment for HCC
patients meeting the Milan criteria with cirrhosis where the
5 yr overall survival ranges from 60% to 80% with excellent
disease-free survival [23]. However, given the limitations in
a v a i l a b l eo r g a n s ,t h ed r o p o u tr a t e ,a n dt h ee c o n o m i ci m p a c t
of OLT, other alternatives such as resection with equivalent
outcomes should be considered in appropriate patients. OLT
in patients exceeding the Milan criteria should be considered
on a selective basis given the excellent outcomes observed by
centers using an extended criterion [24]. Patients beyond the
Milan criteria may be downstaged using locoregional ther-
apies. Following a period of observation after downstaging,
patients who meet Milan criteria may be considered for OLT
[15].
Bridge therapies are often used to prevent progression of
HCC while on the transplant list. The speciﬁc aims are: (1)
avoid drop out due to HCC progression, (2) increase tumor-
free survival after OLT, (3) down stage advanced HCC to
enable liver transplantation, and (4) avoid delay of OLT afterInternational Journal of Hepatology 3
favorable response [25]. The common therapies utilized are
RFA, TACE, percutaneous ethanol injections (PEI) and liver
resection [25–29]. TACE and RFA should be considered to
bridge patients due to the low morbidity and the favorable
responses associated with these techniques that may reduce
drop out in patients with an expected wait period of greater
than 6 month prior to OLT. Liver resection should also
be considered for appropriate patients where it may delay
and/or avoid the need for OLT [15].
4.NonoperativeTherapiesforCombined
ModalityTreatmentofHCC
Most patients with HCC present with advanced liver disease
and are therefore not candidates for liver transplantation,
resection, or ablative procedures. However, most patients
may beneﬁt from palliative procedures that include TACE,
transarterial radioembolization (TARE), external beam
radiotherapy, and systemic therapy with sorafenib. Patient
selection for any of these therapies is based on patient and
tumor factors and decisions regarding treatment approaches
should be made in a multidisciplinary setting that includes a
hepatologist, interventional radiologist, and a surgeon [30].
TACE has been shown in randomized trials to increase
time to progression and overall survival in patients with
unresectable HCC compared to best supportive therapy or
transarterial embolization [31, 32]. Based on this, TACE
is a standard for intermediate-\advanced-stage unresectable
HCCeveninthe settingofportal veinthrombosis (excluding
main portal vein) where there is a proven survival beneﬁt. It
isalsousefulinpredictingtumorbiologyinthepretransplant
setting when used for bridging or downstaging patients.
Emerging data regarding the use of drug eluting micro-
spheres TACE are encouraging due to the comparable eﬃ-
cacywith TACE and the potential for decreased toxicity[30].
Sorafenib which is an anti-VEGF receptor and raf kinase
inhibitor is approved for the treatment of unresectable HCC
and is the standard agent for systemic therapy of advanced
HCC based on a level 1 data [33]. Radiographic responses
to sorafenib are a poor parameter to determine response
to therapy. Tumor necrosis as determined by triphasic CT
m a yb ea na c c u r a t es u r r o g a t em a r k e ro fe ﬃcacy but further
data is required. The extent of cirrhosis appears to inﬂuence
the outcomes of sorafenib therapy. Newer novel agents
require further study before recommendations can be made
regarding their use [30].
The use of yttrium 90 radioembolization is safe and eﬃ-
cacious in well-selected groups of patient where acceptable
response rates and improvements in overall survival have
beenreported[34].Thesubsetsofpatientswherethismodal-
ity should be considered are patients being downstaged or
bridged with the intention of OLT, patients with malignant
portal vein thrombosis where both TACE and OLT are con-
traindicated, and patients with advanced disease [30, 35, 36].
Recently, there has been a resurgent interest in the use
of radiotherapy for HCC, driven by technological advances
and an improved understanding of hepatic tolerance to
radiotherapy. External beam radiation therapy and photon
irradiation have been shown to induce acceptable response
rates and provide local control to unresectable tumors [37].
With improved understanding of hepatic tolerance rates,
radiotherapy will further expand the treatment options for
patients with HCC, and multimodal strategies that include
radiotherapy merit further study [30].
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